Evonik (EVK) AI Stock Analysis

• Market Cap: €6.18B
• Dividend Yield: 8.82%
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): 65.1
• Beta (1Y): 0.96
• Revenue Growth: -5.92%
• EPS Growth: -58.33%
• Country: DE
• Employees: 31,585
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.27
• Shares Outstanding: 466,000,000
• 10 Day Avg. Volume: 1,023,876
• 30 Day Avg. Volume: 1,242,903
• PEG Ratio: -0.24
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.51
• P/FCF Ratio: 8.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €14.78
• Price Target Upside: 11.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: €13.00 ▼(-2.03% Downside)

Evonik's overall stock score reflects a challenging financial performance with pressure on revenue growth and profitability. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and technical indicators suggesting oversold conditions. The high P/E ratio raises valuation concerns, though the strong dividend yield offers some appeal. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Stable Balance Sheet

A moderate debt-to-equity ratio indicates a balanced approach to leverage, providing financial stability and flexibility for future investments.

Strong Cash Conversion

A strong cash conversion ratio suggests efficient operations, enhancing the company's ability to reinvest in growth and manage financial obligations.

Strategic Partnerships

Strategic partnerships enhance product offerings and market reach, supporting long-term revenue growth and competitive positioning.

Negative Factors

Declining Revenue Growth

A declining revenue growth rate reflects market challenges, potentially impacting the company's ability to expand and maintain market share.

Low Profitability

Low profitability margins indicate pressure on earnings, which can hinder the company's ability to generate shareholder value and reinvest in growth.

Negative Free Cash Flow Growth

Negative free cash flow growth suggests declining cash generation capabilities, potentially limiting the company's financial flexibility and investment capacity.

Evonik Business Overview & Revenue Model

Company Description

Evonik Industries AG is a global leader in specialty chemicals, headquartered in Essen, Germany. The company operates through several segments, including Nutrition & Care, Resource Efficiency, Performance Materials, and Specialty Additives. Evonik's core products range from high-performance materials and additives used in various industries to nutritional products for animal feed and personal care applications, showcasing its commitment to innovation and sustainability.

How the Company Makes Money

Evonik generates revenue primarily through the sale of specialty chemicals and materials across diverse industries. Its main revenue streams include the production and supply of additives, surfactants, and polymers that cater to sectors such as automotive, construction, consumer goods, and agriculture. The Nutrition & Care segment, which focuses on animal nutrition and health, is a significant contributor to earnings, driven by global demand for sustainable feed solutions. Additionally, Evonik has established strategic partnerships with key players in various industries to enhance its product offerings and expand market reach, thereby bolstering its financial performance. The company's commitment to research and development also plays a crucial role in creating innovative solutions that meet evolving customer needs, further driving revenue growth.

Evonik Financial Statement Overview

Summary

Evonik presents a stable financial profile with strong cash flow generation and a balanced capital structure. While income growth faces headwinds, the company's operational efficiency and prudent financial management provide resilience against market challenges.

Income Statement

Evonik demonstrates a stable performance in its income statement. The TTM (Trailing-Twelve-Months) gross profit margin is healthy, and the EBIT and EBITDA margins reflect operational efficiency. However, there is a notable decline in revenue and net income from the previous year, indicating challenges in maintaining growth momentum.

Balance Sheet

The balance sheet shows a solid equity base with a moderate debt-to-equity ratio, indicating a balanced capital structure. While the return on equity has improved, it remains essential to monitor potential risks due to the relatively high total debt levels.

Cash Flow

The cash flow statement is robust, with consistent free cash flow generation and a strong operating cash flow to net income ratio. The company manages its capital expenditure well, ensuring sustainable cash flow despite fluctuations in net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.27B	15.16B	15.27B	18.49B	14.96B	12.20B
Gross Profit	3.22B	3.74B	3.39B	4.23B	4.03B	3.37B
EBITDA	1.78B	1.76B	991.00M	2.07B	2.18B	1.76B
Net Income	95.00M	222.00M	-465.00M	540.00M	746.00M	465.00M
Balance Sheet
Total Assets	18.55B	19.75B	21.26B	21.81B	22.28B	20.90B
Cash, Cash Equivalents and Short-Term Investments	454.00M	618.00M	1.03B	1.12B	919.00M	1.06B
Total Debt	4.49B	3.78B	4.25B	4.22B	3.64B	3.84B
Total Liabilities	10.13B	10.65B	12.28B	10.75B	12.91B	12.80B
Stockholders Equity	8.35B	9.02B	8.91B	10.97B	9.29B	8.01B
Cash Flow
Free Cash Flow	409.00M	873.00M	801.00M	785.00M	929.00M	771.00M
Operating Cash Flow	1.22B	1.71B	1.59B	1.65B	1.81B	1.73B
Investing Cash Flow	-696.00M	-663.00M	-653.00M	-777.00M	-1.07B	-570.00M
Financing Cash Flow	-483.00M	-1.33B	-823.00M	-672.00M	-856.00M	-1.73B

Evonik Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVK, the sentiment is Neutral. The current price of 13.27 is above the 20-day moving average (MA) of 13.12, below the 50-day MA of 13.89, and below the 200-day MA of 16.77, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 76.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:EVK.

Evonik Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FPE	70 Outperform	€4.46B	13.20	16.00%	3.91%	1.42%	-0.40%
BNR	64 Neutral	€7.16B	17.12	9.62%	4.24%	-3.35%	-23.06%
WCH	62 Neutral	€3.42B	14.17	―	3.64%	-10.63%	-23.15%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
EVK	54 Neutral	€6.18B	65.08	1.08%	8.82%	-5.92%	-58.33%
1COV	52 Neutral	€12.44B	-24.68	-7.19%	―	-5.27%	-75.47%
LXS	46 Neutral	€1.51B	-6.20	-5.69%	0.57%	-6.82%	71.94%